Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in HER2-expressing Biliary Tract Cancer
NCT07606599Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BL-M07D1 in biliary tract cancer (BTC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Overall Survival at 24 months. Started Jul 2026; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07606599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606599.